First Reliance Bancshares Reports Third Quarter 2026 Results

First Reliance reported Q3 2026 net income of $2.7 million, or $0.33 per diluted share, unchanged year over year; operating earnings rose to $2.9 million from $2.7 million. Net interest income increased 4.6% to $9.9 million, while net interest margin was 3.73%, up 7 bps year over year but down 1 bp sequentially. Nonperforming assets rose to $6.6 million, or 0.59% of assets, from $626,000, primarily due to one $5.5 million collateralized loan. Regulatory and shareholder approvals for the Colony Bank merger are complete, with closing scheduled for November 1, 2026.

Analysis

The key underwriting question is not the announced scale benefit but the quality of the earnings and funding being brought into Colony Bankcorp (CBAN). First Reliance’s near-flat quarterly NIM, weaker mortgage-banking income, higher operating costs, and quarter-end loan contraction point to limited standalone earnings momentum entering the combination. Its deposit mix has also shifted away from noninterest-bearing balances year over year; if that persists, scale could arrive with a higher marginal funding cost rather than immediate operating leverage.

The $5.5 million nonaccrual is a single collateralized loan, not evidence of broad portfolio deterioration. Still, the simultaneous reserve release makes validation of collateral value, repayment resolution, and subsequent criticized-loan trends important. Rising rates are a two-sided integration input: they may help asset yields over time, but the larger AFS unrealized loss pressures reported tangible book and could complicate the market’s assessment of deal dilution. Do not extrapolate these First Reliance figures to CBAN’s standalone results.

Near term, closing is the catalyst; the more consequential 6–18 month test is whether deposit retention, credit outcomes, and expense integration support the promised strategic rationale. Deal consideration, pro forma capital/TBV impact, credit marks, and quantified cost savings are not supplied, so merger-arbitrage or a directional CBAN trade lacks adequate underwriting. The contrarian risk is that investors focus on approval and scale while underweighting funding mix and integration execution; conversely, treating one secured loan as a systemic credit signal would overstate the downside.

Key Decisions for Investors

• No immediate directional CBAN position on this release alone. Before trading the closing event, verify transaction consideration/exchange mechanics, expected pro forma tangible-book dilution, credit marks, and any quantified cost saves; without these, neither deal spread nor accretion is assessable.
• Treat the November 1 close as a near-term event, not proof of value creation. Revisit CBAN after the first combined-company disclosures; focus on deposit retention and cost of deposits, integration expense versus plan, and pro forma capital rather than headline asset scale.
• Monitor First Reliance’s $5.5 million nonaccrual for collateral support and resolution, plus criticized loans and subsequent provision decisions. A broader deterioration or additional large nonaccruals would falsify the single-loan containment case; recovery without further migration would reduce the credit concern.
• Track AFS marks and tangible-book treatment as rates move, alongside the June 2027 systems-conversion timeline. Further book-value pressure, deposit outflows, or delayed integration milestones would argue against assuming near-term merger synergies.